{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:30:37Z","timestamp":1776472237502,"version":"3.51.2"},"reference-count":150,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T00:00:00Z","timestamp":1697068800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular and Cellular Cardiology Plus"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jmccpl.2023.100053","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T16:02:19Z","timestamp":1697212939000},"page":"100053","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Endothelin-based markers for endothelial dysfunction in chemotherapy-induced cardiotoxicity"],"prefix":"10.1016","volume":"6","author":[{"given":"Gabrielle","family":"Boutin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jale","family":"Yuzugulen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md Zahidul Islam","family":"Pranjol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jmccpl.2023.100053_bb0005","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"5","key":"10.1016\/j.jmccpl.2023.100053_bb0010","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.7150\/ijbs.58786","article-title":"Potential of exosomes as diagnostic biomarkers and therapeutic carriers for doxorubicin-induced cardiotoxicity","volume":"17","author":"Tian","year":"2021","journal-title":"Int J Biol Sci"},{"issue":"1","key":"10.1016\/j.jmccpl.2023.100053_bb0015","doi-asserted-by":"crossref","first-page":"R106","DOI":"10.1530\/VB-21-0013","article-title":"Breast cancer chemotherapy vascular toxicity: a review of mediating mechanisms and exercise as a potential therapeutic","volume":"3","author":"Mclaughlin","year":"2021","journal-title":"Vasc Biol"},{"issue":"15","key":"10.1016\/j.jmccpl.2023.100053_bb0020","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMsa060185","article-title":"Chronic health conditions in adult survivors of childhood cancer","volume":"355","author":"Oeffinger","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jmccpl.2023.100053_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/bcr2901","article-title":"Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study","volume":"13","author":"Patnaik","year":"2011","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.jmccpl.2023.100053_bb0030","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fcvm.2020.00026","article-title":"Cardiotoxicity of anthracyclines","volume":"7","author":"Cardinale","year":"2020","journal-title":"Front Cardiovasc Med"},{"issue":"8","key":"10.1016\/j.jmccpl.2023.100053_bb0035","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1080\/17425255.2017.1351547","article-title":"Chemotherapy-induced cardiotoxicity in children","volume":"13","author":"Bansal","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"13","key":"10.1016\/j.jmccpl.2023.100053_bb0040","doi-asserted-by":"crossref","first-page":"e579","DOI":"10.1161\/CIR.0000000000000641","article-title":"Cardio-oncology: vascular and metabolic perspectives: a scientific statement from the American Heart Association","volume":"139","author":"Campia","year":"2019","journal-title":"Circulation."},{"issue":"23","key":"10.1016\/j.jmccpl.2023.100053_bb0045","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1161\/CIRCULATIONAHA.115.010484","article-title":"Cardio-oncology: how new targeted cancer therapies and precision medicine can inform cardiovascular discovery","volume":"132","author":"Bellinger","year":"2015","journal-title":"Circulation."},{"issue":"4\u20135","key":"10.1016\/j.jmccpl.2023.100053_bb0050","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.clinbiochem.2014.10.013","article-title":"Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity","volume":"48","author":"Christenson","year":"2015","journal-title":"Clin Biochem"},{"issue":"21","key":"10.1016\/j.jmccpl.2023.100053_bb0055","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.3390\/cancers13215426","article-title":"Role of cardiac biomarkers in cancer patients","volume":"13","author":"Semeraro","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jmccpl.2023.100053_bb0060","first-page":"923","article-title":"The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection","author":"Jin","year":"2015","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"10.1016\/j.jmccpl.2023.100053_bb0065","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.cell.2022.12.014","article-title":"From ABCD to E for endothelin in resistant hypertension","volume":"186","author":"Abraham","year":"2023","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.jmccpl.2023.100053_bb0070","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1124\/pr.115.011833","article-title":"Endothelin","volume":"68","author":"Davenport","year":"2016","journal-title":"Pharmacol Rev"},{"issue":"8","key":"10.1016\/j.jmccpl.2023.100053_bb0075","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41569-020-0347-2","article-title":"Vascular toxic effects of cancer therapies","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"10.1016\/j.jmccpl.2023.100053_bb0080","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41581-021-00489-1","article-title":"Renal microvascular endothelial cell responses in sepsis-induced acute kidney injury","volume":"18","author":"Molema","year":"2022","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"10.1016\/j.jmccpl.2023.100053_bb0085","first-page":"H705","article-title":"Detrimental effects of chemotherapy on human coronary microvascular function","volume":"317","author":"Hader","year":"2019","journal-title":"Am J Phys Heart Circ Phys"},{"issue":"10","key":"10.1016\/j.jmccpl.2023.100053_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2021.100932","article-title":"Hyperhomocysteinemia as a link of chemotherapy-related endothelium impairment","volume":"47","author":"Avagimyan","year":"2022","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.jmccpl.2023.100053_bb0095","article-title":"Endothelial dysfunction as a complication of anti-cancer therapy","volume":"108116","author":"Terwoord","year":"2022","journal-title":"Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.jmccpl.2023.100053_bb0100","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nrneph.2010.14","article-title":"Endothelin-receptor antagonists for treating hypertension","volume":"6","author":"Weir","year":"2010","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"10.1016\/j.jmccpl.2023.100053_bb0105","doi-asserted-by":"crossref","first-page":"11372","DOI":"10.1038\/s41598-021-90779-2","article-title":"C1q\/TNF-related protein-9 ameliorates hypoxia-induced pulmonary hypertension by regulating secretion of endothelin-1 and nitric oxide mediated by AMPK in rats","volume":"11","author":"Jin","year":"2021","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.jmccpl.2023.100053_bb0110","first-page":"139","article-title":"Burden of cardiac arrhythmias in patients with anthracycline-related cardiomyopathy","volume":"3","author":"Mazur","year":"2017","journal-title":"JACC: Clin Electrophysiol"},{"issue":"2","key":"10.1016\/j.jmccpl.2023.100053_bb0115","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014708","article-title":"Changes in cardiovascular biomarkers with breast cancer therapy and associations with cardiac dysfunction","volume":"9","author":"Demissei","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.jmccpl.2023.100053_bb0120","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.2459\/JCM.0000000000000376","article-title":"Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy","volume":"17","author":"Madeddu","year":"2016","journal-title":"J Cardiovasc Med"},{"issue":"4","key":"10.1016\/j.jmccpl.2023.100053_bb0125","first-page":"1132","article-title":"Cardiotoxicity of chemotherapy and targeted agents","volume":"11","author":"Mudd","year":"2021","journal-title":"Am J Cancer Res"},{"issue":"1","key":"10.1016\/j.jmccpl.2023.100053_bb0130","first-page":"15","article-title":"Anthracycline-induced cardiotoxicity in the chemotherapy treatment of breast cancer: preventive strategies and treatment","volume":"11","author":"Cai","year":"2019","journal-title":"Mol Clin Oncol"},{"issue":"17","key":"10.1016\/j.jmccpl.2023.100053_bb0135","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1093\/eurjpc\/zwac170","article-title":"Management and treatment of cardiotoxicity due to anticancer drugs: 10 questions and answers","volume":"29","author":"Chianca","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jmccpl.2023.100053_bb0140","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00002018-200022040-00002","article-title":"Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention","volume":"22","author":"Pai","year":"2000","journal-title":"Drug Saf"},{"issue":"8","key":"10.1016\/j.jmccpl.2023.100053_bb0145","doi-asserted-by":"crossref","first-page":"806","DOI":"10.3390\/medicina57080806","article-title":"Cardiotoxicity associated with chemotherapy used in gastrointestinal tumours","volume":"57","author":"Radulescu","year":"2021","journal-title":"Medicina"},{"issue":"3","key":"10.1016\/j.jmccpl.2023.100053_bb0150","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1177\/1535370217746383","article-title":"Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients","volume":"243","author":"Yu","year":"2018","journal-title":"Exp Biol Med"},{"issue":"4","key":"10.1016\/j.jmccpl.2023.100053_bb0155","doi-asserted-by":"crossref","first-page":"267","DOI":"10.14797\/mdcj-15-4-267","article-title":"Prevention and treatment of chemotherapy-induced cardiotoxicity","volume":"15","author":"Avila","year":"2019","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"1","key":"10.1016\/j.jmccpl.2023.100053_bb0160","doi-asserted-by":"crossref","first-page":"e002661","DOI":"10.1161\/CIRCHEARTFAILURE.115.002661","article-title":"Cancer therapy\u2013related cardiac dysfunction and heart failure: part 1: definitions, pathophysiology, risk factors, and imaging","volume":"9","author":"Bloom","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"24","key":"10.1016\/j.jmccpl.2023.100053_bb0165","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management","volume":"53","author":"Yeh","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jmccpl.2023.100053_bb0170","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00280-016-3152-1","article-title":"The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy","volume":"78","author":"Ahlmann","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"10.1016\/j.jmccpl.2023.100053_bb0175","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1038\/bmt.2017.188","article-title":"Acute and fatal cardiotoxicity following high-dose cyclophosphamide in a patient undergoing autologous stem cell transplantation for systemic sclerosis despite satisfactory cardiopulmonary screening","volume":"52","author":"Martin","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"17","key":"10.1016\/j.jmccpl.2023.100053_bb0180","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/jnci\/djs317","article-title":"Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study","volume":"104","author":"Bowles","year":"2012","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.jmccpl.2023.100053_bb0185","doi-asserted-by":"crossref","first-page":"760","DOI":"10.7150\/ijbs.65258","article-title":"Underlying the mechanisms of doxorubicin-induced acute cardiotoxicity: oxidative stress and cell death","volume":"18","author":"Kong","year":"2022","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.jmccpl.2023.100053_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-019-0751-0","article-title":"Changing hearts and minds: improving outcomes in cancer treatment-related cardiotoxicity","volume":"21","author":"Shelburne","year":"2019","journal-title":"Curr Oncol Rep"},{"issue":"9","key":"10.1016\/j.jmccpl.2023.100053_bb0195","first-page":"24","article-title":"Chemotherapy agents that cause cardiotoxicity","volume":"42","author":"Thomas","year":"2017","journal-title":"US Pharm"},{"issue":"22","key":"10.1016\/j.jmccpl.2023.100053_bb0200","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation."},{"issue":"8","key":"10.1016\/j.jmccpl.2023.100053_bb0205","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jmccpl.2023.100053_bb0210","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1136\/heartjnl-2017-312103","article-title":"Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention","volume":"104","author":"Henriksen","year":"2018","journal-title":"Heart."},{"key":"10.1016\/j.jmccpl.2023.100053_bb0215","series-title":"Advances in precision medicine oncology","article-title":"Molecular-level understanding of the anticancer action mechanism of anthracyclines","author":"Shandilya","year":"2020"},{"issue":"2","key":"10.1016\/j.jmccpl.2023.100053_bb0220","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/ejhf.1610","article-title":"Myocardial dysfunction in long-term breast cancer survivors treated at ages 40\u201350 years","volume":"22","author":"Jacobse","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jmccpl.2023.100053_bb0225","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10549-020-05930-w","article-title":"Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study","volume":"185","author":"Jacobse","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.jmccpl.2023.100053_bb0230","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1512942","article-title":"HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy","volume":"8","author":"Triulzi","year":"2019","journal-title":"Oncoimmunology."},{"issue":"10075","key":"10.1016\/j.jmccpl.2023.100053_bb0235","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","article-title":"11 years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial","volume":"389","author":"Cameron","year":"2017","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.jmccpl.2023.100053_bb0240","doi-asserted-by":"crossref","first-page":"7572","DOI":"10.1002\/cam4.4283","article-title":"Exercise intervention decreases acute and late doxorubicin-induced cardiotoxicity","volume":"10","author":"Wang","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.jmccpl.2023.100053_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-018-0696-8","article-title":"Pharmacogenetics of chemotherapy-induced cardiotoxicity","volume":"20","author":"Chang","year":"2018","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"10.1016\/j.jmccpl.2023.100053_bb0250","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jchf.2018.09.001","article-title":"Long-term risk of heart failure in breast cancer patients after adjuvant chemotherapy with or without trastuzumab","volume":"7","author":"Banke","year":"2019","journal-title":"JACC Heart Fail"},{"issue":"11","key":"10.1016\/j.jmccpl.2023.100053_bb0255","first-page":"3599","article-title":"Anticancer therapeutics: a brief account on wide refinements","volume":"10","author":"Rehman","year":"2020","journal-title":"Am J Cancer Res"},{"issue":"2","key":"10.1016\/j.jmccpl.2023.100053_bb0260","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3390\/pharmaceutics15020369","article-title":"Co-encapsulation of simvastatin and doxorubicin into pH-sensitive liposomes enhances antitumoral activity in breast cancer cell lines","volume":"15","author":"Duarte","year":"2023","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.jmccpl.2023.100053_bb0265","first-page":"401","article-title":"Functionalized liposomes for targeted breast cancer drug delivery","volume":"24","author":"Nel","year":"2023","journal-title":"Bioact Mater"},{"issue":"3","key":"10.1016\/j.jmccpl.2023.100053_bb0270","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.radcr.2022.12.048","article-title":"Delayed doxorubicin induced cardiomyopathy in a breast cancer patient: a case report","volume":"18","author":"Song","year":"2023","journal-title":"Radiol Case Rep"},{"key":"10.1016\/j.jmccpl.2023.100053_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114599","article-title":"Cancer treatment-related cardiovascular disease: current status and future research priorities","volume":"190","author":"Nonaka","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jmccpl.2023.100053_bb0280","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s10741-020-09948-6","article-title":"Research progress of biomarkers in early detection of chemotherapy-induced cardiotoxicity","volume":"26","author":"Gai","year":"2021","journal-title":"Heart Fail Rev"},{"issue":"14","key":"10.1016\/j.jmccpl.2023.100053_bb0285","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1080\/14656566.2022.2124107","article-title":"Pharmacological strategies to reduce anthracycline-associated cardiotoxicity in cancer patients","volume":"23","author":"Stansfeld","year":"2022","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"10.1016\/j.jmccpl.2023.100053_bb0290","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41571-019-0299-9","article-title":"Towards personalized treatment for early stage HER2-positive breast cancer","volume":"17","author":"Goutsouliak","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.jmccpl.2023.100053_bb0295","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10585-021-10106-x","article-title":"Cardiooncology\u2014dealing with modern drug treatment, long-term complications, and cancer survivorship","volume":"38","author":"de Wall","year":"2021","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.jmccpl.2023.100053_bb0300","series-title":"Advances in precision medicine oncology","author":"Arnouk","year":"2021"},{"issue":"1","key":"10.1016\/j.jmccpl.2023.100053_bb0305","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10741-020-09977-1","article-title":"Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system\u2014from molecular mechanisms to therapeutic applications","volume":"27","author":"Sobczuk","year":"2022","journal-title":"Heart Fail Rev"},{"issue":"10","key":"10.1016\/j.jmccpl.2023.100053_bb0310","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.7150\/ijbs.7502","article-title":"The vascular endothelium and human diseases","volume":"9","author":"Rajendran","year":"2013","journal-title":"Int J Biol Sci"},{"issue":"9","key":"10.1016\/j.jmccpl.2023.100053_bb0315","first-page":"2933","article-title":"Biomarkers of inflammation, hypercoagulability and endothelial injury predict early asymptomatic doxorubicin-induced cardiotoxicity in breast cancer patients","volume":"10","author":"Todorova","year":"2020","journal-title":"Am J Cancer Res"},{"issue":"8","key":"10.1016\/j.jmccpl.2023.100053_bb0320","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1097\/00004872-199816080-00001","article-title":"Endothelin as a regulator of cardiovascular function in health and disease","volume":"16","author":"Haynes","year":"1998","journal-title":"J Hypertens"},{"issue":"1","key":"10.1016\/j.jmccpl.2023.100053_bb0325","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2183\/pjab.82.17","article-title":"Endothelin and endothelial dysfunction","volume":"82","author":"Masaki","year":"2006","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"10.1016\/j.jmccpl.2023.100053_bb0330","series-title":"Vascular surgery in oncology","first-page":"409","article-title":"Vascular toxicity and cardiotoxicity of cancer treatment","author":"Macedo","year":"2022"},{"issue":"2","key":"10.1016\/j.jmccpl.2023.100053_bb0335","doi-asserted-by":"crossref","first-page":"89","DOI":"10.15420\/icr.2019.12","article-title":"Coronary artery vasospasm induced by 5-fluorouracil: proposed mechanisms, existing management options and future directions","volume":"14","author":"Chong","year":"2019","journal-title":"Interv Cardiol"},{"issue":"3","key":"10.1016\/j.jmccpl.2023.100053_bb0340","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10557-021-07181-3","article-title":"The molecular mechanisms of cardiotoxicity induced by HER2, VEGF, and tyrosine kinase inhibitors: an updated review","volume":"36","author":"Wu","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"issue":"4","key":"10.1016\/j.jmccpl.2023.100053_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2023.101591","article-title":"Chemotherapy induced cardiotoxicity: a state of the art review on general mechanisms, prevention, treatment and recent advances in novel therapeutics","volume":"48","author":"Abdul-Rahman","year":"2023","journal-title":"Curr Probl Cardiol"},{"issue":"3","key":"10.1016\/j.jmccpl.2023.100053_bb0350","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001624","article-title":"Plasma pro-endothelin-1 peptide concentrations rise in chronic kidney disease and following selective endothelin a receptor antagonism","volume":"4","author":"Dhaun","year":"2015","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.jmccpl.2023.100053_bb0355","article-title":"Endothelial dysfunction and hypertension","volume":"64","author":"Brandes","year":"2014","journal-title":"J Am Heart Assoc Hypertens"},{"issue":"5","key":"10.1016\/j.jmccpl.2023.100053_bb0360","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ctrv.2011.09.002","article-title":"Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications","volume":"38","author":"Soultati","year":"2012","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.jmccpl.2023.100053_bb0365","article-title":"Increased vascular contractility in hypertension results from impaired endothelial calcium signaling","volume":"74","author":"Wilson","year":"2019","journal-title":"Journal of American Heart Association Hypertension."},{"issue":"12","key":"10.1016\/j.jmccpl.2023.100053_bb0370","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/14779072.2018.1540301","article-title":"Pathophysiology of essential hypertension: an update","volume":"16","author":"Saxena","year":"2018","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"3","key":"10.1016\/j.jmccpl.2023.100053_bb0375","first-page":"302","article-title":"Permissive cardiotoxicity","volume":"4","author":"Porter","year":"2022","journal-title":"JACC: CardioOncology"},{"issue":"20","key":"10.1016\/j.jmccpl.2023.100053_bb0380","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1161\/CIR.0000000000000617","article-title":"Fourth universal definition of myocardial infarction (2018)","volume":"138","author":"Thygesen","year":"2018","journal-title":"Circulation."},{"issue":"23","key":"10.1016\/j.jmccpl.2023.100053_bb0385","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1056\/NEJM199712043372302","article-title":"Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I","volume":"337","author":"Hamm","year":"1997","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.jmccpl.2023.100053_bb0390","first-page":"181","article-title":"ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: comments from the Dutch ACS working group","volume":"2017","author":"Damman","year":"2015","journal-title":"Neth Hear J"},{"key":"10.1016\/j.jmccpl.2023.100053_bb0395","series-title":"Current advances in osteosarcoma","first-page":"181","article-title":"Anthracycline-induced cardiotoxicity: causes, mechanisms, and prevention","author":"Bhagat","year":"2020"},{"issue":"1","key":"10.1016\/j.jmccpl.2023.100053_bb0400","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","article-title":"Anthracycline chemotherapy and cardiotoxicity","volume":"31","author":"McGowan","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"10.1016\/j.jmccpl.2023.100053_bb0405","doi-asserted-by":"crossref","first-page":"7954","DOI":"10.1038\/s41598-021-87209-8","article-title":"Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer","volume":"11","author":"Lakhani","year":"2021","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.jmccpl.2023.100053_bb0410","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab","volume":"63","author":"Ky","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jmccpl.2023.100053_bb0415","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/ehf2.12589","article-title":"Cardiac biomarkers for the detection of cardiotoxicity in childhood cancer\u2014a meta-analysis","volume":"7","author":"Michel","year":"2020","journal-title":"ESC Heart Fail"},{"issue":"22","key":"10.1016\/j.jmccpl.2023.100053_bb0420","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","article-title":"Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy","volume":"109","author":"Cardinale","year":"2004","journal-title":"Circulation."},{"issue":"3","key":"10.1016\/j.jmccpl.2023.100053_bb0425","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.flm.2017.09.003","article-title":"Release of cardiac troponin from healthy and damaged myocardium","volume":"1","author":"Wu","year":"2017","journal-title":"Front Lab Med"},{"issue":"5","key":"10.1016\/j.jmccpl.2023.100053_bb0430","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nm.4087","article-title":"Human induced pluripotent stem cell\u2013derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity","volume":"22","author":"Burridge","year":"2016","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.jmccpl.2023.100053_bb0435","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","article-title":"Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab","volume":"5","author":"Sawaya","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jmccpl.2023.100053_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107863","article-title":"The natriuretic peptide system in heart failure: diagnostic and therapeutic implications","volume":"227","author":"Kuwahara","year":"2021","journal-title":"Pharmacol Ther"},{"issue":"1971","key":"10.1016\/j.jmccpl.2023.100053_bb0445","first-page":"1","article-title":"Myocardial strain: a clinical review","author":"Brady","year":"2022","journal-title":"Ir J Med Sci"},{"key":"10.1016\/j.jmccpl.2023.100053_bb0450","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11936-018-0641-z","article-title":"Role of biomarkers in prediction of cardiotoxicity during cancer treatment","volume":"20","author":"Tan","year":"2018","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.jmccpl.2023.100053_bb0455","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12265-020-10042-3","article-title":"The role of biomarkers in cardio-oncology","volume":"13","author":"Ananthan","year":"2020","journal-title":"J Cardiovasc Transl Res"},{"issue":"16","key":"10.1016\/j.jmccpl.2023.100053_bb0460","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.jmccpl.2023.100053_bb0465","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018143","article-title":"Cardiotoxicity and cardiovascular biomarkers in patients with breast cancer: data from the GeparOcto-GBG 84 trial","volume":"9","author":"R\u00fcger","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"10.1016\/j.jmccpl.2023.100053_bb0470","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cardfail.2016.04.003","article-title":"The utility of point-of-care biomarkers to detect cardiotoxicity during anthracycline chemotherapy: a feasibility study","volume":"22","author":"Lenihan","year":"2016","journal-title":"J Card Fail"},{"issue":"12","key":"10.1016\/j.jmccpl.2023.100053_bb0475","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/14779072.2020.1828063","article-title":"Is the true clinical value of high-sensitivity troponins as a biomarker of risk? The concept that detection of high-sensitivity troponin \u2018never means nothing\u2019","volume":"18","author":"Hinton","year":"2020","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"9","key":"10.1016\/j.jmccpl.2023.100053_bb0480","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jacc.2018.12.046","article-title":"Recommendations for institutions transitioning to high-sensitivity troponin testing","volume":"73","author":"Januzzi","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.jmccpl.2023.100053_bb0485","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.hlc.2021.03.272","article-title":"Prognostic value of high-sensitivity troponin T after on-pump coronary artery bypass graft surgery","volume":"30","author":"Nellipudi","year":"2021","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.jmccpl.2023.100053_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.trac.2021.116477","article-title":"Heart failure biomarkers BNP and NT-proBNP detection using optical labels","volume":"146","author":"Goryacheva","year":"2022","journal-title":"TrAC Trends Anal Chem"},{"issue":"1\u20132","key":"10.1016\/j.jmccpl.2023.100053_bb0495","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.cca.2008.10.011","article-title":"Comparison between analytical performances of polyclonal and monoclonal electrochemiluminescence immunoassays for NT-proBNP","volume":"400","author":"Prontera","year":"2009","journal-title":"Clin Chim Acta"},{"issue":"2","key":"10.1016\/j.jmccpl.2023.100053_bb0500","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10741-021-10105-w","article-title":"Biomarkers for the diagnosis and management of heart failure","volume":"27","author":"Castiglione","year":"2022","journal-title":"Heart Fail Rev"},{"issue":"4","key":"10.1016\/j.jmccpl.2023.100053_bb0505","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jchf.2013.04.008","article-title":"Racial\/ethnic differences in B-type natriuretic peptide levels and their association with care and outcomes among patients hospitalized with heart failure: findings from Get With The Guidelines-Heart Failure","volume":"1","author":"Krim","year":"2013","journal-title":"JACC Heart Fail"},{"issue":"3","key":"10.1016\/j.jmccpl.2023.100053_bb0510","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ejhf.2115","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"36","key":"10.1016\/j.jmccpl.2023.100053_bb0515","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.jmccpl.2023.100053_bb0520","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.amjcard.2020.01.025","article-title":"N-terminal pro B-type natriuretic peptide and high-sensitivity cardiac troponin as markers for heart failure and cardiovascular disease risks according to glucose status (from the Multi-Ethnic Study of Atherosclerosis [MESA])","volume":"125","author":"Nguyen","year":"2020","journal-title":"Am J Cardiol"},{"issue":"10","key":"10.1016\/j.jmccpl.2023.100053_bb0525","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1007\/s00063-003-1304-7","article-title":"Brain natriuretic peptide","volume":"98","author":"Kruger","year":"2003","journal-title":"Med Klin"},{"issue":"10","key":"10.1016\/j.jmccpl.2023.100053_bb0530","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.009427","article-title":"Reference ranges for NT-proBNP (N-terminal pro-B-type natriuretic peptide) and risk factors for higher NT-proBNP concentrations in a large general population cohort","volume":"15","author":"Welsh","year":"2022","journal-title":"Circ Heart Fail"},{"issue":"15","key":"10.1016\/j.jmccpl.2023.100053_bb0535","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1093\/eurheartj\/ehq163","article-title":"Age-dependent values of N-terminal pro-B-type natriuretic peptide are superior to a single cut-point for ruling out suspected systolic dysfunction in primary care","volume":"31","author":"Hildebrandt","year":"2010","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.jmccpl.2023.100053_bb0540","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26164812","article-title":"Fluorescent immunoassays for detection and quantification of cardiac troponin I: a short review","volume":"26","author":"Radha","year":"2021","journal-title":"Molecules."},{"issue":"2","key":"10.1016\/j.jmccpl.2023.100053_bb0545","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.cclet.2021.07.017","article-title":"Washing-free chemiluminescence immunoassay for rapid detection of cardiac troponin I in whole blood samples","volume":"33","author":"Zhao","year":"2022","journal-title":"Chin Chem Lett"},{"issue":"4","key":"10.1016\/j.jmccpl.2023.100053_bb0550","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1021\/acssensors.0c00064","article-title":"One-step digital immunoassay for rapid and sensitive detection of cardiac troponin I","volume":"5","author":"Wang","year":"2020","journal-title":"ACS Sens"},{"key":"10.1016\/j.jmccpl.2023.100053_bb0555","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.plabm.2015.04.002","article-title":"Analytical evaluation of a BNP assay on the new point-of-care platform respons\u00aeIQ","volume":"2","author":"Fellner","year":"2015","journal-title":"Pract Lab Med"},{"key":"10.1016\/j.jmccpl.2023.100053_bb0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.steroids.2020.108701","article-title":"An overview of the classical and tissue-derived renin-angiotensin-aldosterone system and its genetic polymorphisms in essential hypertension","volume":"163","author":"Abdel Ghafar","year":"2020","journal-title":"Steroids."},{"key":"10.1016\/j.jmccpl.2023.100053_bb0565","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2013.00161","article-title":"The role of tissue renin-angiotensin-aldosterone system in the development of endothelial dysfunction and arterial stiffness","volume":"4","author":"Aroor","year":"2013","journal-title":"Front Endocrinol"},{"issue":"6","key":"10.1016\/j.jmccpl.2023.100053_bb0570","article-title":"Endothelin: 30 years from discovery to therapy","volume":"74","author":"Yanagisawa","year":"2019","journal-title":"J Am Heart Assoc Hypertens"},{"issue":"13","key":"10.1016\/j.jmccpl.2023.100053_bb0575","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics13132277","article-title":"Could endothelin-1 be a promising neurohormonal biomarker in acute heart failure?","volume":"13","author":"Dmour","year":"2023","journal-title":"Diagnostics"},{"issue":"6","key":"10.1016\/j.jmccpl.2023.100053_bb0580","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/ejhf.1378","article-title":"Multi-organ dysfunction\/injury on admission identifies acute heart failure patients at high risk of poor outcome","volume":"21","author":"Zymlinski","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"22","key":"10.1016\/j.jmccpl.2023.100053_bb0585","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1161\/CIRCULATIONAHA.122.063327","article-title":"Endothelin-1, outcomes in patients with heart failure and reduced ejection fraction, and effects of dapagliflozin: findings from DAPA-HF","volume":"147","author":"Yeoh","year":"2023","journal-title":"Circulation."},{"issue":"1","key":"10.1016\/j.jmccpl.2023.100053_bb0590","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tcm.2019.01.007","article-title":"Endothelin-1 levels and cardiovascular events","volume":"30","author":"Jankowich","year":"2020","journal-title":"Trends Cardiovasc Med"},{"issue":"12","key":"10.1016\/j.jmccpl.2023.100053_bb0595","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.3390\/jcm11123547","article-title":"Upregulation of Endothelin-1 may predict chemotherapy-induced cardiotoxicity in women with breast cancer","volume":"11","author":"Krishnarao","year":"2022","journal-title":"J Clin Med"},{"issue":"11","key":"10.1016\/j.jmccpl.2023.100053_bb0600","doi-asserted-by":"crossref","first-page":"959","DOI":"10.5551\/jat.47324","article-title":"Prognostic value of plasma big Endothelin-1 level among patients with three-vessel disease: a cohort study","volume":"26","author":"Zhang","year":"2019","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jmccpl.2023.100053_bb0605","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ijcard.2016.12.082","article-title":"Plasma big endothelin-1 levels at admission and future cardiovascular outcomes: a cohort study in patients with stable coronary artery disease","volume":"230","author":"Zhou","year":"2017","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.jmccpl.2023.100053_bb0610","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00005-014-0310-1","article-title":"The role of endothelin-1 and endothelin receptor antagonists in inflammatory response and sepsis","volume":"63","author":"Kowalczyk","year":"2015","journal-title":"Arch Immunol Ther Exp"},{"issue":"1","key":"10.1016\/j.jmccpl.2023.100053_bb0615","doi-asserted-by":"crossref","first-page":"4956","DOI":"10.1038\/s41598-017-05365-2","article-title":"Characterisation of preproendothelin-1 derived peptides identifies endothelin-like domain peptide as a modulator of Endothelin-1","volume":"7","author":"Yuzugulen","year":"2017","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.jmccpl.2023.100053_bb0620","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/00005344-199202000-00004","article-title":"Regional hemodynamic effects and clearance of endothelin-1 in humans: renal and peripheral tissues may contribute to the overall disposal of the peptide","volume":"19","author":"Gasic","year":"1992","journal-title":"J Cardiovasc Pharmacol"},{"issue":"25","key":"10.1016\/j.jmccpl.2023.100053_bb0625","doi-asserted-by":"crossref","first-page":"14954","DOI":"10.1016\/S0021-9258(18)63795-0","article-title":"The human preproendothelin-1 gene: complete nucleotide sequence and regulation of expression","volume":"264","author":"Inoue","year":"1989","journal-title":"J Biol Chem"},{"issue":"23","key":"10.1016\/j.jmccpl.2023.100053_bb0630","doi-asserted-by":"crossref","first-page":"9529","DOI":"10.1073\/pnas.86.23.9529","article-title":"Endothelin-like pulmonary vasoconstrictor peptide release by alpha-thrombin","volume":"86","author":"Moon","year":"1989","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"10.1016\/j.jmccpl.2023.100053_bb0635","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0006-2952(95)02036-5","article-title":"Molecular pharmacology of endothelin converting enzymes","volume":"51","author":"Turner","year":"1996","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jmccpl.2023.100053_bb0640","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/bs.apha.2016.05.002","article-title":"Endothelin-1: biosynthesis, signaling and vasoreactivity","volume":"77","author":"Houde","year":"2016","journal-title":"Adv Pharmacol"},{"issue":"2","key":"10.1016\/j.jmccpl.2023.100053_bb0645","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/01.CIR.0000105701.98663.D4","article-title":"Conditional cardiac overexpression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice","volume":"109","author":"Yang","year":"2004","journal-title":"Circulation."},{"issue":"12","key":"10.1016\/j.jmccpl.2023.100053_bb0650","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1016\/j.peptides.2005.05.010","article-title":"Proteolytic processing pattern of the endothelin-1 precursor in vivo","volume":"26","author":"Struck","year":"2005","journal-title":"Peptides."},{"issue":"5","key":"10.1016\/j.jmccpl.2023.100053_bb0655","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nbt0510-431","article-title":"Biomarkers on a roll","volume":"28","year":"2010","journal-title":"Nat Biotechnol"},{"issue":"25","key":"10.1016\/j.jmccpl.2023.100053_bb0660","article-title":"Evaluation of urinary and plasma endothelin-like domain peptide (ELDP) in chronic kidney disease","volume":"93","author":"Yuzugulen","year":"2013","journal-title":"Life Sci"},{"issue":"4","key":"10.1016\/j.jmccpl.2023.100053_bb0665","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/ejhf.1697","article-title":"Evaluation of kidney function throughout the heart failure trajectory\u2013a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"Mullens","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"16","key":"10.1016\/j.jmccpl.2023.100053_bb0670","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.jacc.2011.11.082","article-title":"Endothelial dysfunction, arterial stiffness, and heart failure","volume":"60","author":"Marti","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"Supplement_4","key":"10.1016\/j.jmccpl.2023.100053_bb0675","doi-asserted-by":"crossref","first-page":"i72","DOI":"10.1093\/ckj\/sfab192","article-title":"Multitargeted interventions to reduce dialysis-induced systemic stress","volume":"14","author":"Canaud","year":"2021","journal-title":"Clin Kidney J"},{"issue":"2","key":"10.1016\/j.jmccpl.2023.100053_bb0680","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ajpath.2014.10.021","article-title":"Chemotherapy-induced pulmonary hypertension: role of alkylating agents","volume":"185","author":"Ranchoux","year":"2015","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jmccpl.2023.100053_bb0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.earlhumdev.2020.105142","article-title":"Cardiovascular biomarkers in the evaluation of patent ductus arteriosus in very preterm neonates: a cohort study","volume":"149","author":"Sellmer","year":"2020","journal-title":"Early Hum Dev"},{"key":"10.1016\/j.jmccpl.2023.100053_bb0690","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40560-017-0219-y","article-title":"C-terminal proendothelin-1 (CT-proET-1) is associated with organ failure and predicts mortality in critically ill patients","volume":"5","author":"Buendgens","year":"2017","journal-title":"J Intensive Care"},{"issue":"2","key":"10.1016\/j.jmccpl.2023.100053_bb0695","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41440-021-00827-7","article-title":"Renal denervation: basic and clinical evidence","volume":"45","author":"Katsurada","year":"2022","journal-title":"Hypertens Res"},{"issue":"1","key":"10.1016\/j.jmccpl.2023.100053_bb0700","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccl.2021.08.001","article-title":"The pathobiology of pulmonary arterial hypertension","volume":"40","author":"Rajagopal","year":"2022","journal-title":"Cardiol Clin"},{"issue":"13","key":"10.1016\/j.jmccpl.2023.100053_bb0705","doi-asserted-by":"crossref","DOI":"10.1172\/JCI149117","article-title":"Breast cancer chemotherapy induces vascular dysfunction and hypertension through a NOX4-dependent mechanism","volume":"132","author":"Szczepaniak","year":"2022","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.jmccpl.2023.100053_bb0710","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00004872-200018030-00006","article-title":"Receptor- and non-receptor-mediated clearance of big-endothelin and endothelin-1: differential effects of acute and chronic ETA receptor blockade","volume":"18","author":"Burkhardt","year":"2000","journal-title":"J Hypertens"},{"issue":"6","key":"10.1016\/j.jmccpl.2023.100053_bb0715","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1373\/clinchem.2005.065581","article-title":"Immunoluminometric assay for measurement of the C-terminal endothelin-1 precursor fragment in human plasma","volume":"52","author":"Papassotiriou","year":"2006","journal-title":"Clin Chem"},{"issue":"12","key":"10.1016\/j.jmccpl.2023.100053_bb0720","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.healun.2013.06.020","article-title":"An exploratory panel of biomarkers for risk prediction in pulmonary hypertension: emerging role of CT-proET-1","volume":"32","author":"Silva Marques","year":"2013","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jmccpl.2023.100053_bb0725","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.629151","article-title":"C-terminal-pro-endothelin-1 adds incremental prognostic value for risk stratification after ischemic stroke","volume":"11","author":"Westphal","year":"2021","journal-title":"Front Neurol"},{"issue":"8","key":"10.1016\/j.jmccpl.2023.100053_bb0730","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41569-019-0176-3","article-title":"Endothelins in cardiovascular biology and therapeutics","volume":"16","author":"Dhaun","year":"2019","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"10.1016\/j.jmccpl.2023.100053_bb0735","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/09674845.2021.1883257","article-title":"Cardiac biomarkers for risk stratification of arrhythmic death in patients with heart failure and reduced ejection fraction","volume":"78","author":"Burger","year":"2021","journal-title":"Br J Biomed Sci"},{"issue":"10","key":"10.1016\/j.jmccpl.2023.100053_bb0740","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1038\/s41366-022-01184-2","article-title":"Mid-regional proadrenomedullin, C-terminal proendothelin-1 values, and disease course are not different in critically ill SARS-CoV-2 pneumonia patients with obesity","volume":"46","author":"van Oers","year":"2022","journal-title":"Int J Obes"},{"issue":"6","key":"10.1016\/j.jmccpl.2023.100053_bb0745","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/s41390-021-01493-8","article-title":"Respiratory morbidity in preterm infants predicted by natriuretic peptide (MR-proANP) and endothelin-1 (CT-proET-1)","volume":"91","author":"Gerull","year":"2022","journal-title":"Pediatr Res"},{"issue":"6","key":"10.1016\/j.jmccpl.2023.100053_bb0750","doi-asserted-by":"crossref","DOI":"10.1172\/JCI148556","article-title":"Targeting the vasculature in cardiometabolic disease","volume":"132","author":"Boutagy","year":"2022","journal-title":"J Clin Invest"}],"container-title":["Journal of Molecular and Cellular Cardiology Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772976123000235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772976123000235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:27:38Z","timestamp":1734568058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772976123000235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":150,"alternative-id":["S2772976123000235"],"URL":"https:\/\/doi.org\/10.1016\/j.jmccpl.2023.100053","relation":{},"ISSN":["2772-9761"],"issn-type":[{"value":"2772-9761","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endothelin-based markers for endothelial dysfunction in chemotherapy-induced cardiotoxicity","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular and Cellular Cardiology Plus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmccpl.2023.100053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100053"}}